New computational tool for detecting prognostic biomarkers in renal cell cancer

19.08.2015

Researchers in Turku Centre for Biotechnology have developed a new computational approach for detecting biomarkers in patient samples. The developed method detects genetic markers that have implication e.g. in predicting cancer patient prognosis and is a powerful tool for analyzing latest genome-wide technologies like RNA-sequencing. The study has recently appeared in the journal of Nucleic Acids Research.

Mathematicians, biologists and oncologists in the University of Turku, Finland, have joined forces to use the method for developing new means for predicting renal cancer (RCC) prognosis. The clinical course of RCC is heterogeneous. Approximately 50% of patients develop metastases after surgery but the life expectancy varies from months to over 15 years. Current prognostic post-nephrectomy markers are based on clinicopathological features but are not sufficiently accurate for predicting patient prognosis and RCC lacks widely accepted genetic markers for prognosis that makes the result of this study clinically prominent.

A joint group of Drs. Laura Elo, Fatemeh Seyednasrollah, Panu Jaakkola and Krista Rantanen analyzed gene expression profiles of 442 ccRCC patients provided by The Cancer Genome Atlas (TCGA) revealing a list of 152 genes playing role in prediction of survival outcomes. The research team validated their findings using an independent Japanese dataset of 100 patients.

– Low overlap of candidate biomarkers detected in different studies has remained a major challenge in clinical applications of genomics. Therefore, improving the overlap is extremely important. This study is a step towards that direction, says Dr. Laura Elo, research director in Computational Biomedicine group.
 
– Remarkably, novel markers include for example a number of proteins that function in transporting different chemical between cells and extracellular space. The work highlights the importance of joining expertise across clinical, experimental and computational experts says Dr. Panu Jaakkola oncologist at Turku University Hospital.
 
 
The article was recently published in Nucleic Acids Research journal


LR
Created 19.08.2015 | Updated 19.08.2015